A major limitation that prevents the use of the Kv10.1 and Kv11.1 blockers in cancer is their adverse effects on cardiac physiology, resulting in prolonged QT intervals, which may further lead to fatal ventricular arrhythmias [144]. Here, KCNH2 is linked to cancer.